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Cowden syndrome (CS) is a difficult-to-recognize multiple hamartoma syndrome with high risks of breast, thyroid, and other cancers.
Germline mutations in PTEN on 10q23 were found to cause 85% of CS when accrued from tertiary academic centers, but prospective
accrual from the community over the last 12 years has revealed a 25% PTEN mutation frequency. PTEN is the phosphatase that has
been implicated in a heritable cancer syndrome and subsequently in multiple sporadic cancers and developmental processes. PTEN
antagonizes the AKT1/PI3K signaling pathway and has roles in cell cycle, migration, cell polarity, and apoptosis. We report that 8 of
91 (8.8%) unrelated CS individuals without germline PTENmutations carried 10 germline PIK3CAmutations (7 missense, 1 nonsense,
and 2 indels) and 2 (2.2%) AKT1mutations. These mutations result in significantly increased P-Thr308-AKT and increased cellular PIP3.
Our observations suggest that PIK3CA and AKT1 are CS susceptibility genes.Germline mutations in PTEN (OMIM 176920) on 10q23
were found in 85% of families with Cowden syndrome
(CS) (OMIM 158350) when accrued from tertiary academic
centers.1,2 Prospective accrual from the community over
the last 12 years has revealed that 25% of CS cases are
due to PTEN mutations;3 10% of CS individuals without
a detected PTEN mutation carry germline SDHx variants4
and ~30% have germline KLLN (OMIM 612105) hyperme-
thylation.5 CS is a clinical mimic and difficult to recog-
nize with broad phenotypic presentations and reduced
penetrance. In this context, identification of additional
predisposition genes would facilitate molecular diagnosis,
predictive testing, genetic counseling, and medical
management. We created a PTEN Cleveland Clinic (CC)
Risk Calculator based on prospective accrual of >3,000
CS and Cowden-like (CSL) individuals and multiple
logistic regression weighted by neoplasia risk in PTEN
mutation positive versus individuals without a detected
PTEN mutation in our cohort compared to that in the
general population and by age of neoplasia onset in
our cohort.3 Increasing CC score correlates with higher
prior probability of finding PTEN mutations. For clinical
purposes, we suggest a threshold of 10 (>3%–5% prior
probability) for consideration of PTEN testing. Based on
this rationale, we selected 91 CS/CSL individuals without
mutations in PTEN or SDHx, or hypermethylation of the
KLLN promoter, and with CC scores ranging from 8 to 54
(adults), with>80% having scores>8 or whomet pediatric
criteria. We sought to determine whether individuals with
high CC scores without alterations in known genes have
mutations in genes encoding proteins immediately down-
stream of PTEN.
Germline genomic DNA from 91 unrelated consenting
(IRB-8458-PTEN) CS/CSL probands, without PTEN/SDHx/
KLLN mutations/alterations, were analyzed by Sanger1Genomic Medicine Institute and Lerner Research Institute, 2Taussig Cancer
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(OMIM 171834), PIK3R1 (OMIM 171833), and PIK3R2
(OMIM 603157) (see Table S1 available online). While
no germline mutations were found in PIK3R1 (NM_
181523.2) and PIK3R2 (NM_005027.2), ten (10.99%) pro-
bands were found to carry germline PIK3CA and AKT1
mutations (NM_006218.2, NM_001014431.1) (Table 1;
Figure 1; Table S2). None of the mutations were found in
96 population controls, dbSNP, or the available data set
in 1000 Genomes Project. To predict the functionality
of the germline mutations, we used MutPred software6
and three-dimensional (3D) protein modeling (Discovery
Studio-3.1, Accelrys Inc) of the mutations within their
respective domains. The MutPred software, which calcu-
lates the probability of a deleterious mutation and corre-
sponding hypothesis of disrupted molecular mechanism,
revealed values between 0.46 and 0.88 for our detected
variants/mutations. MutPred values between 0.45 and
0.75 predict for benign variations and values >0.75 patho-
genic mutations. Three-dimensional modeling revealed
that all of the mutations altered polarity and conforma-
tion and/or stability of specific domains, leading to or
resulting in inappropriate exposure or hiding of key
amino acid functional domains. Two mutations in PIK3CA
c.353G>A and c.1145G>A that result in p.Gly118Asp
(MutPred ¼ 0.496) and p.Arg382Lys (MutPred ¼ 0.464)
alterations, respectively, had 3D plots showing significant
structural alterations (Figures S1 and S2); furthermore,
the germline p.Gly118Asp has been reported as a somatic
change with functionality in a sporadic malignancy.
PIK3CA encodes p110a, the catalytic subunit of PI3K,
which adds a phosphate to phosphatidylinositol-4,5-
biphosphate (PIP2) to form phosphatidylinositol-3,4,5-
triphosphate (PIP3) at the cellular membrane.7–10 PIP3
recruits PH domain-containing proteins, e.g., AKT1 to theInstitute, Cleveland Clinic, Cleveland, OH 44195, USA; 3Department of
Western Reserve University School of Medicine, Cleveland, OH 44106, USA
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Table 1. CS/CSL Individuals with Germline AKT1 and PIK3CA Mutations
Sample CCF IDs Gene Exon Mutations MutPred Gender Age CC Score
CCF03121-01-001DG AKT1 2 c.73C>T, p.Arg25Cys 0.879 F 38 8
CCF04333-01-001LM AKT1 12 c.1303A>C, p.Thr435Pro 0.595 F 47 22
CCF03451-01-001DC PIK3CA 2 c.353G>A, p.Gly118Asp 0.496 M 32 12
CCF04880-01-001MQ PIK3CA 2 c.403G>A, p.Glu135Lys 0.677 F 54 13
CCF00102-01-001GG PIK3CA 3 c.652G>A, p.Glu218Lys 0.598 F 44 22
CCF03330-01-001LM PIK3CA 5 c.1066G>A, p.Val356Ile 0.503 F 35 10
CCF02069-01-001CS PIK3CA 5 c.1145G>A, p.Arg382Lys 0.464 M 47 22
CCF04477-01-001FN PIK3CA 9 c.1634A>C, p.Glu545Ala and c.1658_1659 delGTinsC,
p. Ser553Thrfs*7
0.769 F 71 13
CCF05779-01-001SC PIK3CA 9 c.1634A>C, p.Glu545Ala and c.1658_1659 delGTinsC
p. Ser553Thrfs*7
0.769 F 27 22
CCF00494-01-001WG PIK3CA 11 c.1895T>G, p.Leu632* N/A M 59 7
CC Score, PTEN Cleveland Clinic Clinical Score for a priori probability of finding PTEN mutations. Accession numbers used are NM_001014431.1 (AKT1) and
NM_006218.2 (PIK3CA).cell membrane.11 We performed western blot analysis for
phospho(P)-AKT1 and p110a in germline protein lysates
extracted from CS-derived lymphoblastoid cells from
AKT1 and PIK3CA mutation-positive individuals and four
controls (Figure 2), using antibodies against P-AKT1Ser473
(Epitomics Inc., Burlingame, CA), P-AKT1Thr308 (Santa
Cruz Biotechnology, CA), p110alpha (Cell Signaling Tech-
nology, Danvers, MA), and actin (Santa Cruz Biotech-
nology). All mutation-positive protein lysates showed
a significant increase of P-Thr308-AKT1 levels (Figures 2A
and 2B). No obvious differences in P-Ser473-AKT1 were
noted between controls and individuals with themutation,
corroborating the specificity of the mutations because
Thr308-AKT1, but not Ser473-AKT, is a phosphorylation
target of p110a12. To assess the impact of PIK3CA muta-
tions on PI3K activity, we used immunofluorescence
to compare PIP3 in lymphoblastoid cell lines derived
from two individuals that carry germline PIK3CA muta-
tions to that fromWT individuals (as described,13 Figure 3).
Lymphoblastoid cells were incubated on poly-L-lysine-
coated slides for 30 min. Cells were then washed with
PBS and then fixed with 100% ice-cold methanol (for
1 min) on slides. Slides were then blocked in 5% goat
serumPBS and incubated sequentiallywith anti-phosphati-
dylinositol PIP3 antibody (MBL International, Woburn,
MA, Cat# D145-3) and Alexa Fluor secondary antibody.The AmSlides were counterstained with DAPI and visualized on
a Leica TCS-SP spectral laser scanning confocalmicroscope.
Counterstaining with DAPI revealed increased levels of
PIP3 in PIK3CA-p.Glu218Lys and moderately increased
levels in PIK3CA-p.Arg382Lys cells compared to wild-type
(WT) (Figure 3). Cells bearing PTEN-p.Arg335* served as
a positive control (Figure 3). Treating the PTEN-p.Arg335*
cells with Wortmannin (PI3K inhibitor) decreased PIP3
levels.
We initially predicted that germline AKT1 mutations
would be more frequent than those in PIK3CA based on
the report that frequent postzygotic somatic AKT1 muta-
tions occur in affected tissues of Proteus syndrome, also
rarely associated with PTEN mutations.14,15 Instead, we
found that 2.2% of CS/CSL probands carried germline
AKT1 mutations (c.73C>T and c.1303A>C, Table 1). The
PH-domain p.Arg25Cys germline change has previously
been reported as a somatic alteration in noninherited can-
cers, with insulin-dependent increased kinase activity16
but abrogation of estradiol-related kinase activity.17
In vitro insulin exposure results in AKT1-p.Arg25Cys
stabilizing p110a and increasing the latter’s activity phos-
phorylating and upregulating AKT1.16 Our western blot
supports this observation, showing tendency toward
increased p110a and a significantly increased phosphory-
lation of AKT1 at Thr308 (Figures 2A and 2B). TheFigure 1. Spectrum of Germline PIK3CA
Mutations in CS/CSL Individuals without
PTEN Germline Mutations
A display of amino acid changes that result
from different germline PIK3CAmutations
in CS/CSL individuals (blue arrows) rela-
tive to PIK3CA functional domains.
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Figure 2. AKT1 and PIK3CAMutations Result in Upregulation of
Phosphorylated P-Thr308-AKT1
(A) Western analysis of peripheral blood protein lysates from CS/
CSL individuals with germline AKT1 and PIK3CA mutations.
Mutation-positive individuals showed modest increase in p110a
levels and marked increased levels of P-Thr308-AKT1 (arrow) but
no detectable difference in P-Ser473-AKT1 and total (T)-AKT1
protein levels compared to controls.
(B) Densitometric analysis of specific signals using Image J soft-
ware. Signals were normalized to actin. A value of 100% was arbi-
trarily assigned to the ratio obtained in the controls (n ¼ 4) and
the relative ratio was made in the individuals with mutations
(n¼8). Two-tailed Student’s t testwas utilized.N.S., not significant.p.Thr435Pro mutation has not been described before but
the end result is increased P-AKT1.
We found that >8.8% CS/CSL probands, without de-
tected PTEN germline mutation, have heterozygous germ-
line PIK3CA mutations but not in genes encoding the
regulatory subunits of PI3K, PIK3R1/PIK3R2 (Table 1).
Somatic mutations in these three genes have been amply
described in solid tumors, including those of the breast,
thyroid, and endometrium18–20. Overall, the somatic
mutational spectra and the germline spectra in PIK3CA
appear different, with the majority of CS/CSL mutations
within the C2-domain. C2 is responsible for p110a recruit-
ment to cellular membranes. C2 mutations have been
shown in vitro to alter charge or conformation enhancing
recruitment of the mutant-p110a to cell membranes.21
Corroborating this, western analysis reveals slightly in-
creased p110a and markedly increased P-Thr308-AKT78 The American Journal of Human Genetics 92, 76–80, January 10, 2(Figure 2A). Recently, postzygotic and mosaic mutations
in the genes encoding various proteins in the AKT/
PI3K signaling pathway have been described in rare
nonneoplasia hemihypertrophy-segmental overgrowth
syndromes.13,22,23 Note that C2-domain PIK3CA muta-
tions are prominent in megalencephaly-capillary malfor-
mation syndrome as well. Among all these syndromes,
including CS/CSL, involvement of the brain and vascular
malformation are not infrequent. Just as we proposed the
term PTEN hamartoma tumor syndrome (PHTS) for any
individual irrespective of clinical presentation carrying a
germline PTEN mutation, we would like to propose the
term PTEN/AKT/PI3K-opathy to encompass this broad
range of phenotypes.
In summary, 11% of Cowden and Cowden-like syn-
drome individuals without detected PTEN/SDHx/KLLN
mutation/alteration carry germline gain-of-function AKT1
or PIK3CA mutations. Together, the PIK3CA and AKT1
pathways represent a novel driver of predisposition to
hamartoma-neoplasia syndromes that may have diag-
nostic, genetic counseling, and therapeutic implications.Supplemental Data
Supplemental Data includes two figures and two tables and
can be found with this article online at http://www.cell.com/
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